Skip to main content
Journal of Vascular Surgery: Venous and Lymphatic Disorders logoLink to Journal of Vascular Surgery: Venous and Lymphatic Disorders
. 2023 Apr 18;11(3):586. doi: 10.1016/j.jvsv.2023.01.001

PRESERVE trial confirms low risk for most inferior vena cava filters, but benefit remains uncertain

David L Dawson 1
PMCID: PMC12245421  PMID: 37080687

The findings reported by Johnson et al1 on the PRESERVE (predicting the safety and effectiveness of inferior vena cava filters) trial, a prospective trial, have confirmed the safety of inferior vena cava (IVC) filters in contemporary practice. Claiming effectiveness is a trickier proposition. Without a control group, it is difficult to discern whether any net benefit results from IVC filter placement.

Relatively low rates of serious thromboembolic complications can be the result of several different factors. The risk of serious pulmonary embolism PE can be high for patients with extensive deep vein thrombosis (DVT), segmental pulmonary emboli, or thrombophilia. However, the incidence of major PE can be expected to be lower for patients with isolated calf vein thrombi, those with incidentally found subsegmental PE, and those without current thromboembolic disease. High- and low-risk patients were considered together. The trial also included patients who had been treated with anticoagulation at some point, and the analysis did not adequately consider how this might have affected the outcomes. Also important to consider, the study protocol did not include routine imaging to assess for recurrent VTE; thus, recognition of new DVT or PE was determined from the clinical assessments.

The authors argued that a randomized controlled trial to evaluate IVC filter effectiveness would be unethical, because denying patients filter placement would be harmful. Reading between the lines, however, it appears the investigators' clinical practices varied highly. A total of 53 sites had enrolled patients for this trial, with 155 patients included at the highest enrolling site. However, most sites had enrolled ≤16 patients, equating to only one patient every 2 to 3 months. Different centers, it seems, had either had significantly different patient populations or substantially different biases in the selection of patients requiring treatment with an IVC filter.

Because of the broad inclusion criteria used in the study, fewer than one half of the patients had had a substantiated or absolute indication for IVC filter placement.2 Those enrolled who might have been reasonably managed without a filter included 498 patients (35% of filter placements) with a planned or recent operation who had current or prior DVT. The investigators did not use consistent guidelines to decide whether an IVC filter was needed, instead of other options such as delaying a nonemergency operation, briefly interrupting anticoagulation therapy for surgery, using nonpharmacologic thromboprophylaxis, or proceeding with the planned operation with the patient receiving anticoagulation therapy. Another 381 patients had had filters places for prophylaxis, “additional protection” from PE during therapeutic anticoagulation, or for another relatively unsupported indication. It seems that equipoise existed for many of the situations for which a decision was needed regarding filter use or nonuse.

Without a comparison of intervention (filter placement) vs medical management and other methods of thromboprophylaxis, no basis exists to claim effectiveness of the intervention. Thus, the title of their report, “Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE): Outcomes at 12 Months,” is inaccurate. The results of this study have not provided physicians with predictive tools to use when deciding whether an IVC filter should be placed.

The opinions or views expressed in this commentary are those of the authors and do not necessarily reflect the opinions or recommendations of the Journal of Vascular Surgery: Venous and Lymphatic Disorders or the Society for Vascular Surgery.

Footnotes

Author conflict of interest: none.

The editors and reviewers of this article have no relevant financial relationships to disclose per the Journal policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.

References

  • 1.Johnson M.S., Spies J.B., Scott K.T., Kato B.S., Mu X., Rectenwald J.E., et al. Predicting the safety and effectiveness of inferior vena cava filters (PRESERVE): outcomes at 12 months. J Vasc Surg Venous Lymphatic Disord. 2023;11:573–585. doi: 10.1016/j.jvsv.2022.11.002. [DOI] [PubMed] [Google Scholar]
  • 2.Kaufman J.A., Barnes G.D., Chaer R.A., Cuschieri J., Eberhardt R.T., Johnson M.S., et al. Society of Interventional Radiology clinical practice guideline for inferior vena cava filters in the treatment of patients with venous thromboembolic disease: developed in collaboration with the American College of Cardiology, American College of Chest physicians, American College of Surgeons Committee on Trauma, American Heart Association, Society for Vascular Surgery, and Society for Vascular Medicine. J Vasc Interv Radiol. 2020;31:1529–1544. doi: 10.1016/j.jvir.2020.06.014. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Vascular Surgery: Venous and Lymphatic Disorders are provided here courtesy of Elsevier

RESOURCES